back to the overview


Ad-hoc-Release; Berlin, December 29, 2006


MOLOGEN AG out-licenses marketing rights for India and receives further upfront payment


  • 2006 most successful year in company history
  • More than EUR 4 million received through licensing deals


The Berlin-based biotechnology company MOLOGEN AG announced today that licensing and marketing rights for MOLOGEN´s innovative cell-based gene-therapy for India were granted to ONCO Life Sciences, Pvt., Ltd.

In the context of the agreement with ONCO Life Sciences, MOLOGEN has received an upfront payment of EUR 2.1 million. Furthermore, ONCO Life Sciences will purchase all individualized therapy components for patients in India from MOLOGEN as stipulated in a separate Purchase and Supply Agreement.

"By granting the license for the Indian market, we open up new potentials for marketing our innovative cancer therapy", said Prof Dr Burghardt Wittig, Chief Executive Officer of MOLOGEN AG. "We expect to start treating the first cancer patients during the next year.

"The license agreement stipulates the licensing and marketing of MOLOGEN´s cell-based gene therapy for the treatment of renal cell carcinoma, colon, breast and lung cancer.ONCO Life Sciences plans to either distribute the therapy through a network of hospitals or to grant a sub-license to a major Indian pharmaceutical company.

ONCO Life Sciences is currently in advanced negotiations to obtain the necessary treatment permission. Pending the approval by the authorities, first patients could be treated in the next year.


MOLOGEN finishes most successful year in company history

With the license agreement for India, MOLOGEN is completing the most successful year in the company history.

MOLOGEN has achieved strategically important milestones in 2006, such as the license agreement with a leading US-based pharmaceutical company for Leishmania, the marketing agreements for a number of Asian countries and India and the Orphan Drug Status for the treatment of renal cell carcinoma for the EU.

Furthermore, MOLOGEN could foster its financial strength by the receipt of license payments of more than EUR 4 million.



MOLOGEN AG is a listed biopharmaceutical company with headquarters in Berlin (Frankfurt Stock Exchange, Regulated Market, ISIN DE0006637200). On the basis of patented technologies (MIDGE and dSLIM), MOLOGEN develops DNA-based vaccines and therapeutic agents for the prevention and treatment of a wide range of serious illnesses.


Disclaimer concerning prognoses

Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial classification numbers, developments of the financial situation, or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for these forward-looking statements. It is not responsible for updating such information, which only represents the state of affairs on the day of publication.


 back to the overview


Investor & Public Relations

  Joerg Petrass

Research & Development

  Dr. Matthias Schroff

Business Development

  Arlett Killat


To subscribe to our Newsletter please

 click here


To view our Reports

  click here